75 related articles for article (PubMed ID: 27356803)
1. BH3-only protein Bim predicts advanced stage of cutaneous melanoma.
Gambichler T; Rooms I; Scholl L; Stockfleth E; Stücker M; Sand M
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1926-1929. PubMed ID: 27356803
[TBL] [Abstract][Full Text] [Related]
2. Bim expression is reduced in human cutaneous melanomas.
Dai DL; Wang Y; Liu M; Martinka M; Li G
J Invest Dermatol; 2008 Feb; 128(2):403-7. PubMed ID: 17637819
[TBL] [Abstract][Full Text] [Related]
3. TAT-Bim induces extensive apoptosis in cancer cells.
Kashiwagi H; McDunn JE; Goedegebuure PS; Gaffney MC; Chang K; Trinkaus K; Piwnica-Worms D; Hotchkiss RS; Hawkins WG
Ann Surg Oncol; 2007 May; 14(5):1763-71. PubMed ID: 17206479
[TBL] [Abstract][Full Text] [Related]
4. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between PUMA and BIM expression in colorectal cancer and tumor invasion, metastasis and prognosis].
Yuan H; Tu SL; He XJ
Zhonghua Wai Ke Za Zhi; 2013 Jun; 51(6):547-51. PubMed ID: 24091272
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
9. Melastatin expression and prognosis in cutaneous malignant melanoma.
Duncan LM; Deeds J; Cronin FE; Donovan M; Sober AJ; Kauffman M; McCarthy JJ
J Clin Oncol; 2001 Jan; 19(2):568-76. PubMed ID: 11208852
[TBL] [Abstract][Full Text] [Related]
10. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
11. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
13. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
[TBL] [Abstract][Full Text] [Related]
14. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
[TBL] [Abstract][Full Text] [Related]
15. SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma.
Pópulo H; Batista R; Sampaio C; Pardal J; Lopes JM; Soares P
PLoS One; 2017; 12(6):e0180392. PubMed ID: 28662141
[TBL] [Abstract][Full Text] [Related]
16. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
17. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
18. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y expression in cutaneous melanoma.
Gilaberte Y; Roca MJ; Garcia-Prats MD; Coscojuela C; Arbues MD; Vera-Alvarez JJ
J Am Acad Dermatol; 2012 Jun; 66(6):e201-8. PubMed ID: 21620518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]